Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...

GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...

The study tested Trulicity alongside Sanofi’s (4SNY) Lantus (insulin glargine), and the combo beat Lantus alone at every measure. The new data is important “because it adds to the dataset on Trulicity ...

The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in ...

Trulicity is a prescription drug prescribed to lower blood glucose levels and treat type diabetes. Although it is FDA approved for treating diabetes it is not approved for weight loss. Despite this ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...